Nicorandil tablets will be in shortage intermittently between November 2025 and March 2026. Availability of the 10 mg and 20 mg strengths of both brands (APO-Nicorandil from Arrotex Pharmaceuticals and Ikotab from Viatris) will vary over this time.
To help patients have continuous access to the medicine they need over this time, we have made a Serious Scarcity Substitution Instrument (SSSI) that starts on 28 November 2025. The SSSI allows a pharmacist to substitute whichever brand and strength of nicorandil is available, if appropriate, without a new prescription.
Nicorandil is indicated for the treatment of chronic stable angina pectoris.
For detailed information about the shortages, the SSSI and important factors when considering a substitution, visit About the shortage of nicorandil tablets.
For more information about SSSIs see Substituting scarce medicines and Serious Scarcity Substitution Instruments (SSSIs).